Iba – Transparency Notification
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)
Louvain-la-Neuve, Belgium, November 22th, 2021, 17.40
Summary of the notification
IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on November 15th, 2020.
In its notification, Norges Bank announces that, following a sale of voting shares, its shareholding in IBA SA has fallen below the 2% threshold for shares with voting rights.
Content of the notification
- Reason for the notification: Acquisition or disposal of voting securities or voting rights
- Persons subject to the notification requirement: Norges Bank, Bankplassen 2, PO Box 1179 Sentrum, 0107 Oslo, Norway
- Date on which the threshold is crossed: 11/11/2021
- Threshold crossed (in %): 2%
- Denominator: 38.254,747
- Full chain of controlled undertakings through which the holding is effectively held
Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.
For further information, please contact:
IBA
Valérie Van Impe
Paralegal
+32 10 203 180
About IBA
IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
Attachment
